Welcome to our dedicated page for uniQure N.V. SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on uniQure N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into uniQure N.V.'s regulatory disclosures and financial reporting.
uniQure N.V. reported that Chief Customer & Strategy Officer Kylie O'Keefe received new equity awards. On March 4, 2026, she was granted stock options for 31,900 shares at an exercise price of $0.00 per share and 19,800 ordinary shares as restricted share units.
The restricted share units vest in three equal annual installments of one-third each, starting on the first anniversary of the grant date, subject to her continued relationship with the company. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
uniQure N.V. executive Kylie O'Keefe filed an initial ownership report, showing existing equity awards in the company. The filing lists 180,000 stock options and 105,000 Ordinary Shares held directly as of the reporting date. Footnotes explain that these positions arise from prior equity grants that vest over time.
Restricted share units granted on June 11, 2025 convert into Ordinary Shares in three equal annual installments, subject to continued service. A stock option granted the same day vests over four years, with 25% vesting after one year and the remainder vesting quarterly until June 11, 2029, also contingent on continued service.
uniQure N.V. CEO and managing director Matthew C. Kapusta reported new equity compensation grants and a small related share sale. He was granted stock options for 113,800 shares at an exercise price of $0.00 per share and 70,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of the grant date, subject to his continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested. In a separate transaction, 14,581 ordinary shares were sold at a weighted average price of $9.06 per share, within a range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Medical Officer Walid Abi-Saab reported new equity awards and a small automatic share sale. He was granted stock options for 67,200 shares at an exercise price of $0.00 and 41,700 restricted share units, each representing the right to receive one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, subject to continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
Upon vesting of restricted share units, 808 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owned 189,669 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported a mix of equity awards and an automatic share sale. She received a grant of 57,200 stock options with an exercise price of $0.00 per share and 35,400 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, contingent on her continued service. The stock options vest 25% after one year and 6.25% quarterly thereafter. In connection with vesting, 3,412 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported a mix of equity awards and an automatic tax-related sale. On March 4, 2026, he received a stock option for 63,900 shares at an exercise price of $0.00 and a grant of 39,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of grant, subject to his continued relationship with the company. On the same date, 12,000 ordinary shares were sold at a weighted average price of $9.06 per share, within a price range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade.
uniQure NV reports a proposed sale of ordinary shares and recent insider dispositions. The filing notifies a proposed sale of 12,000 ordinary shares through Citigroup Global Markets on 03/04/2026. The notice also lists 24,333 restricted stock units vesting on 03/04/2026 as compensation. Recent reported dispositions by Christian Klemt total 18, + (6,217 and 12,832) ordinary shares sold in February–March 2026 with reported proceeds shown in the excerpt.
uniQure NV submitted a Form 144 disclosing the proposed sale of 33,000 ordinary shares underlying restricted stock units that vest on 03/04/2026. The filing also reports prior open-market sales by Matthew Kapusta of 12,378 shares on 02/25/2026 ($295,306.90) and 34,437 shares on 03/02/2026 ($342,586.16).
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an automatic open-market sale of 34,437 ordinary shares on March 2, 2026 at an average price of $9.95 per share. The filing explains the shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic instructions, so the sale was not a discretionary trade. After this transaction, Kapusta held 604,639 ordinary shares. The reported price reflects a weighted average from multiple trades between $9.67 and $10.25 per share.